Pfizer India (PFIZER) AGM 2025 summary

Opening remarks and agenda

• The 74th AGM was convened virtually, ensuring broad shareholder participation and compliance with regulatory guidelines.

• The meeting marked the company's 75th year in India, celebrating its legacy and achievements.

• The agenda included adoption of financial statements, declaration of dividend, director reappointments, and auditor appointments.

Financial performance review

• Sales revenue for FY 2024-25 reached INR 2,128.36 crore, a 2.3% increase over the previous year.

• Profit before tax rose 36.2% to INR 1,016.09 crore, aided by a one-time gain from the Thane land sale.

• EBITDA margin improved to 32.4% from 29% last year, with gross margin held at 61.9% despite cost pressures.

• Key brands like Prevenar, Eliquis, and Meropenem drove volume-led growth.

Board and executive committee updates

• New board members Lakshman, Krishna Kumar, and Sonia Singh were welcomed, while contributions of outgoing directors were acknowledged.

• No attrition in top management during the year; overall attrition rate remained below 15%.